How should Samarth Kulkarni, CEO of CRISPR Therapeutics, guide the company at a time when its path-breaking gene-editing treatment for two rare diseases struggles commercially?
How should Samarth Kulkarni, CEO of CRISPR Therapeutics, guide the company at a time when its path-breaking gene-editing treatment for two rare diseases struggles commercially?
What are the key commercial and ethical considerations of new genetic technologies, from the standpoint of all stakeholders?